Contraception
Volume 74, Issue 5 , Pages 359-366 , November 2006

Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives

Received 10 February 2006 ,Revised 26 May 2006 ,Accepted 6 June 2006.

References 

  1. Kaunitz AM. Menstruation: choosing whether… and when. Contraception. 2000;62:277–284
  2. American College of Obstetricians and Gynecologists . Premenstrual syndrome: clinical management guidelines for obstetrician–gynecologists. ACOG Pract Bull. 2000;15:1–9
  3. Kjerulff KH, Erickson BA, Langenberg PW. Chronic gynecological conditions reported by US women: findings from the National Health Interview Survey, 1984 to 1992. Am J Public Health. 1996;86:195–199
  4. Curtis KM, Hillis SD, Kieke BA, Brett KM, Marchbanks PA, Peterson HB. Visits to emergency departments for gynecologic disorders in the United States, 1992–1994. Obstet Gynecol. 1998;91:1007–1012
  5. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol. 1982;144:655–660
  6. Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women?. Lancet. 2000;355:922–924
  7. Dawood MY. Dysmenorrhea. Clin Obstet Gynecol. 1990;33:168–178
  8. Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol. 2002;100:683–687
  9. Sulak PJ, Carl J, Gopalakrishnan I, Coffee A, Kuehl TJ. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception. 2004;70:281–287
  10. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol. 1997;89:179–183
  11. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59:357–362
  12. Dayal M, Barnhart KT. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med. 2001;19:295–303
  13. French L. Dysmenorrhea. Am Fam Physician. 2005;71:285–291
  14. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol. 1990;97:588–594
  15. Protheroe J. Modern management of menorrhagia. J Fam Plann Reprod Health Care. 2004;30:118–122
  16. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss — a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45:320–351
  17. Cole S. Menstrual blood loss and haematological indices. J Reprod Fertil. 1971;27:158
  18. Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update. 2002;8:60–67
  19. Fraser IS. Treatment of menorrhagia. Baillieres Clin Obstet Gynaecol. 1989;3:391–402
  20. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol. 1984;149:788–793
  21. Chimbira TH, Anderson AB, Turnbull A. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. Br J Obstet Gynaecol. 1980;87:603–609
  22. Minjarez DA, Bradshaw KD. Abnormal uterine bleeding in adolescents. Obstet Gynecol Clin North Am. 2000;27:63–78
  23. Munro MG, Lukes AS. Abnormal uterine bleeding and underlying hemostatic disorders: report of a consensus process. Fertil Steril. 2005;84:2335–2337
  24. Clarke A, Black N, Rowe P, Mott S, Howle K. Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynaecol. 1995;102:611–620
  25. Astrup K, Olivarius Nde F, Moller S, Gottschau A, Karlslund W. Menstrual bleeding patterns in pre- and perimenopausal women: a population-based prospective diary study. Acta Obstet Gynecol Scand. 2004;83:197–202
  26. Johannes CB, Crawford SL. Menstrual bleeding, hormones, and the menopausal transition. Semin Reprod Endocrinol. 1999;17:299–309
  27. Weiss G. Menstrual irregularities and the perimenopause. J Soc Gynecol Investig. 2001;8(1 Suppl Proceedings):S65–S66
  28. Gowers W. Epilepsy and other chronic diseases: their causes, symptoms and treatment. New York: William Wood & Co; 1885;
  29. Herzog AG. Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsia. 1991;32(Suppl 6):S27–S33
  30. Svalheim S, Tauboll E, Bjornenak T, et al. Do women with epilepsy have increased frequency of menstrual disturbances?. Seizure. 2003;12:529–533
  31. Wheeler JM. Epidemiology of endometriosis-associated infertility. J Reprod Med. 1989;34:41–46
  32. Rawson JM. Prevalence of endometriosis in asymptomatic women. J Reprod Med. 1991;36:513–515
  33. Strathy JH, Molgaard CA, Coulam CB, Melton LJ. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril. 1982;38:667–672
  34. Verkauf BS. Incidence, symptoms, and signs of endometriosis in fertile and infertile women. J Fla Med Assoc. 1987;74:671–675
  35. Carter JE. Combined hysteroscopic and laparoscopic findings in patients with chronic pelvic pain. J Am Assoc Gynecol Laparosc. 1994;2:43–47
  36. Demco L. Mapping the source and character of pain due to endometriosis by patient-assisted laparoscopy. J Am Assoc Gynecol Laparosc. 1998;5:241–245
  37. Koninckx PR, Oosterlynck D, D'Hooghe T, Meuleman C. Deeply infiltrating endometriosis is a disease whereas mild endometriosis could be considered a non-disease. Ann N Y Acad Sci. 1994;734:333–341
  38. Silberstein S, Merriam G. Sex hormones and headache 1999 (menstrual migraine). Neurology. 1999;53(4 Suppl 1):S3–S13
  39. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63:351–353
  40. Martin VT. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep. 2004;8:229–237
  41. Silberstein SD, Merriam GR. Sex hormones and headache. J Pain Symptom Manage. 1993;8:98–114
  42. The ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod. 2001;16:1527–1535
  43. Thomas K, Vankrieken L. Inhibition of ovulation by low-dose monophasic contraceptive containing gestodene. Am J Obstet Gynecol. 1990;163:1404–1410
  44. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47:583–590
  45. Egarter C, Putz M, Strohmer H, Speiser P, Wenzl R, Huber J. Ovarian function during low-dose oral contraceptive use. Contraception. 1995;51:329–333
  46. Coney P, DelConte A. The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol. Am J Obstet Gynecol. 1999;181:53–58
  47. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–77
  48. Spona J, Feichtinger W, Kindermann C, Wunsch C, Brill K. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception. 1996;54:299–304
  49. Rossmanith WG, Steffens D, Schramm G. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. Contraception. 1997;56:23–30
  50. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72:115–120
  51. Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril. 2003;80:34–42
  52. Hamilton CJ, Hoogland HJ. Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. Am J Obstet Gynecol. 1989;161:1159–1162
  53. Birtch RL, Olatunbosun OA, Pierson RA. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception. 2006;73:235–243
  54. Baerwald AR, Pierson RA. Endometrial development in association with ovarian follicular waves during the menstrual cycle. Ultrasound Obstet Gynecol. 2004;24:453–460
  55. Connell EB. Contraception in the prepill era. Contraception. 1999;59:7S–10S
  56. Loudon NB, Foxwell M, Potts DM, Guild AL, Short RV. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. BMJ. 1977;2:487–490
  57. Gladwell M. John Rock's Error. New Yorker. 2000;52–63
  58. Westhoff C, Kaunitz A. An overview of menstruation. Female Patient. 2002;(Suppl Apr):4–7
  59. Eaton SB, Pike MC, Short RV, et al. Women's reproductive cancers in evolutionary context. Q Rev Biol. 1994;69:353–367
  60. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68:89–96
  61. Anderson FD, Hait H, Hsiu J, Thompson-Graves AL, Wilborn WH, Williams RF. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception. 2005;71:55–59
  62. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol. 2001;98:771–778
  63. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9–13
  64. Machado RB, Fabrini P, Cruz AM, Maia E, da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg). Contraception. 2004;70:365–370
  65. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003;101:653–661
  66. Lambert J, Newton W. Continuous use of oral contraceptives reduces bleeding. J Fam Pract. 2003;52:601–602
  67. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005;CD004695
  68. Aubeny E, Buhler M, Colau JC, Vicaut E, Zadikian M, Childs M. The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives. Eur J Contracept Reprod Health Care. 2004;9:267–277
  69. Killick SR, Bancroft K, Oelbaum S, Morris J, Elstein M. Extending the duration of the pill-free interval during combined oral contraception. Adv Contracept. 1990;6:33–40
  70. Schrager S. Abnormal uterine bleeding associated with hormonal contraception. Am Fam Physician. 2002;65:2073–2080
  71. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–582
  72. Apter D, Borsos A, Baumgartner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003;8:37–51
  73. ACOG Practice Bulletin . The use of hormonal contraception in women with coexisting medical conditions. Number 18, July 2000. Int J Gynaecol Obstet. 2001;75:93–106
  74. Kadir RA, Sabin CA, Pollard D, Lee CA, Economides DL. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia. 1998;4:836–841
  75. Ward CL. Hemorrhaging at menarche: a case report. J Fam Pract. 1992;34:351–354
  76. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003;80:560–563
  77. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–266
  78. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–1149
  79. Schneider MB, Fisher M, Friedman SB, Bijur PE, Toffler AP. Menstrual and premenstrual issues in female military cadets: a unique population with significant concerns. J Pediatr Adolesc Gynecol. 1999;12:195–201
  80. Bennell K, White S, Crossley K. The oral contraceptive pill: a revolution for sportswomen?. Br J Sports Med. 1999;33:231–238
  81. Davis AJ. Advances in contraception. Obstet Gynecol Clin North Am. 2000;27:597–610[vii]
  82. Kaunitz AM. Oral contraceptive use in perimenopause. Am J Obstet Gynecol. 2001;185:S32–S37

PII: S0010-7824(06)00260-5

doi: 10.1016/j.contraception.2006.06.003

Contraception
Volume 74, Issue 5 , Pages 359-366 , November 2006

Article Tools

* Image Usage & Resolution